insights_auto
为什么 FARN 上涨了 4.11%?
深入探索chevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 38.00
arrow_upward
+4.11%(+1.50) 1 天
10月14日, GMT+1 08:21:52 · GBX
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 FARN 生成关键数据洞见…
开盘价
GBX 36.70
最高价
GBX 38.00
最低价
GBX 36.70
市值
7690.99万
平均成交量
4.12万
成交量
384.00
52 周最高价
GBX 193.58
52 周最低价
GBX 34.00
每股收益
-GBX 0.10
流通股数
3102.79万
员工人数
36
开盘价
GBX 36.70
最高价
GBX 38.00
最低价
GBX 36.70
市值
7690.99万
平均成交量
4.12万
成交量
384.00
52 周最高价
GBX 193.58
52 周最低价
GBX 34.00
每股收益
-GBX 0.10
流通股数
3102.79万
员工人数
36
新闻报道
来自网络来源和新闻合作伙伴
Traders Union
·
5小时前
Ryan Detrick：遵循中期选举年后的市场规律，S&P 500 自 2026 年 3 月 30 日以来上涨约 18%
FOREX.com
·
1天前
油价与美元齐涨 道琼斯指数逆势三连阳
www.tmgm.com
·
10小时前
道琼斯工业平均指数回吐因财报带来的500点涨幅
资料
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy简介